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transplant in myeloma patients treated with this regimen, but
without Xcellerated T Cells. The T cell receptor repertoire of
leukapheresis samples as measured by V	 spectratyping demon-
strates marked skewing. Following the Xcellerate Process, the
repertoire returns to a more normal pattern (n  5; p  0.01). In
addition, the T cell repertoire measured 25 days following T cell
infusion (Day 28 posttransplant) demonstrates a more normal
pattern than prior to T cell infusion (n  5). This is in marked
contrast to the severe skewing of T cell receptor diversity normally
seen in myeloma patients following autologous stem cell transplan-
tation (Mariani et al, BJH 2001). Data on clinical outcomes will be
presented.
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LONG TERM OUTCOME FOLLOWING AUTOLOGOUS AND ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR
LYMPHOMA
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Armitage, J.O. University of Nebraska Medical center, Omaha, NE
Follicular lymphoma (FL) accounts for approximately 25-35% of
all cases of non-Hodgkin’s Lymphoma (NHL). Autologous
(ASCT) and allogeneic (alloSCT) hematopoietic stem cell trans-
plantation can induce prolonged remissions in patients with FL,
and studies of alloSCT demonstrate very low relapse rates and
evidence of a plateau on event-free survival (EFS) curves, suggest-
ing the possibility that some patients may be cured with this
modality. We present the long-term outcome in 204 patients with
FL treated with ASCT (n  186) or alloSCT (n  18) between
04/83 and 05/98. For ASCT and alloSCT groups respectively the
median age was 45 vs. 39 years and the median time from diagnosis
to transplant 27 vs 24 months. The majority of patients in both
groups had follicular grade 2 histology, and the conditioning reg-
imen was cyclophosphamide/total body irradiation (Cy/TBI) in
54% of ASCT and 72% of alloSCT. The median follow-up of
surviving patients is 7.8 years (range 1.7 to 19.2 years). Patients
who received an alloSCT had a superior ﬁve-year EFS (76% vs.
41%; p  0.034), but not overall survival (OS) (76% vs. 61%; p 
0.18). To control for the possible confounding effect of preparative
regimen we performed a limited analysis of all patients undergoing
transplantation with Cy/TBI, and found that patients undergoing
alloSCT had superior EFS (p  0.034) and a trend toward im-
proved OS (p  0.18) compared with ASCT. Multivariate analysis
of patients undergoing ASCT demonstrated an inferior EFS in
patients who received 3 prior chemotherapies (hazard ratio [HR]
 3.5; 95% conﬁdence interval [CI]  1.8-7.0, p  0.001) and in
patients 60 years of age (HR  4.7; 95% CI  1.6-13.8, p 
0.001). Variables predicting for an increased risk of death in ASCT
included3 prior chemotherapies (HR 5.0; 95% CI 2.4-10.6,
p 0.0001), age60 years (HR 9.2; 95% CI 2.8-30, p 0.001),
female gender (HR  2.4; 95% CI  1.2-4.9, p  0.013), and the
presence of resistant disease (HR  4.9; 95% CI  1.8-13.6, p 
0.01). In conclusion, this data offers some evidence that with
adequate follow-up alloSCT leads to superior EFS compared with
ASCT, but because of morbidity/mortality associated with al-
loSCT OS is similar in both groups. Notwithstanding issues of
selection bias, the observation that these differences are not ac-
counted for by the intensity of the preparative regimen suggests
that a lack of tumor contamination, an allogeneic graft-versus-
lymphoma effect, or both may be responsible for the improved
outcome.
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Background: 90Y-Zevalin was the 1st FDA-approved RIT for
treatment of pts with relapsed or refractory CD20 low-grade,
follicular, or transformed B-cell NHL, including rituximab-refrac-
tory NHL. Two COH clinical trials are currently investigating
whether standard (0.4 mCi/kg) or escalated doses of 90Y-Zevalin
can be combined safely with myeloablative regimens for ASCT.
Methods/Results: 1) A dose escalation study of 90Y-Zevalin with
dosimetric guidance (maximum radiation dose to the liver of 1000
cGy)  high-dose VP-16  cyclophosphamide (CY) has accrued
26 pts who are evaluable for efﬁcacy and safety. Median age was 49
(25-58). Median dose of 90Y-Zevalin delivered was 71 mCi (37-105
mCi). All pts with measurable disease achieved remission, except
one pt had a positive PET scan. 4 pts received IF-XRT to sites of
prior bulky disease. Median day to ANC 1,000 was 10 days
(8-17). Median days to platelet count 50, 000 was 20 (12-123).
With a median follow-up of 20 months (range 1-40), 21 pts (81%)
are alive and in remission. 2) The standard-dose study of 90Y-
Zevalin (0.4 mCi/kg)  high-dose BEAM has accrued 12 pts,
primarily over the age of 60. Dosimetry was not performed. Me-
dian age was 61 (56-78). All pts engrafted promptly after ASCT
and there were no transplant-related deaths. The median total dose
of 90Y-Zevalin was 32 mCi (range: 20.7-40). Because stem cell
support was used, a maximum 40 mCi dose of Zevalin was allowed.
With a median follow-up of 9 months (range, 4-16), 2 pts have
relapsed, and one of these died from progressive disease. The
remaining 10 pts (83%) are well without evidence of NHL. Con-
clusions: Results from the dose escalation study suggest that high-
dose 90Y-Zevalin can be safely administered with high-dose VP-
16/CY; that high-dose 90Y-Zevalin can be used in place of TBI
without the need for a lead-shielded isolation room; and that this
new high-dose combination is effective in heavily pre-treated pts
with poor-risk NHL. Results from the second study indicate that
the combination of conventional-dose 90Y-Zevalin  high-dose
BEAM is a well-tolerated and easily administrated ASCT regimen
for older pts with aggressive CD20 NHL and does not require
dosimetry. These preliminary results taken in aggregate suggest
that incorporation of 90Y-Zevalin into novel SCT regimens pro-
vides a targeted intensiﬁcation of the transplant regimen and po-
tentially increased anti-tumor activity without added toxicity.
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90Y Zevalin was added to high-dose BEAM followed by auto-
transplant in 22 patients with relapsed or refractory CD20 NHL
with the goal of increasing progression-free and overall survival
(PFS, OS). Cohorts of 3-6 patients were treated at doses calculated
to result in increasing radiation exposure(100, 300, 500, 700 cGy)
to the critical organ (liver, lung or kidney). On D -22, rituximab(R)
250 mg/m2 was administered followed by the imaging dose of 111In
Zevalin (5 mCi). Imaging was performed immediately and at 4, 24,
72, and 144 hours post-injection; dosimetry was performed on D
-15. On D -14, R at 250 mg/m2 was administered followed by 90Y
Zevalin at a dose calculated to deliver the cohort-prescribed ab-
sorbed radiation dose to the critical organ. On D -6 through -1,
patients received BEAM. On D 0, a minimum of 2.0  106
CD34 cells/kg was infused and G-CSF 5 g/kg SQ daily was
begun. The median age was 53 (range: 25-72). 5 patients had
mantle cell lymphoma, 9 had diffuse aggressive NHL, 4 had low
grade NHL, and 4 had transformed NHL. The majority (55%)
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